
Testosterone can increase skin oiliness and acne, and androgen signaling can contribute to scalp hair loss in susceptible men. These effects depend on tissue biology and predisposition as well as hormone exposure. Acne or thinning hair does not by itself prove a high testosterone level. Treatment should identify the skin or hair condition, review the actual testosterone regimen and address the problem without assuming an additional hormone drug is necessary.123
Key points
- Acne involves oil production, blocked follicles and inflammation, not simply poor hygiene.1
- DHT-pathway trials support a role in pattern hair loss, but do not quantify an individual TRT user's risk.3
- A local gel rash and androgen-related acne are different problems.2
How can testosterone affect skin and hair differently?
Androgen effects depend on the tissue receiving the signal. In skin, androgens can increase sebaceous-gland activity and oil production. Acne develops through a combination of follicular blockage, sebum, bacteria and inflammation. On the scalp, androgen-sensitive pattern hair loss involves different follicular biology, including signaling through dihydrotestosterone, or DHT. 1 3
That is why increased facial or body hair and thinning scalp hair can coexist. Hair growth is not one uniform process across the body. A change in one area does not tell you exactly what is happening elsewhere or reveal the concentration of testosterone in blood.
This distinction also limits supplement claims. A product advertised as broadly blocking DHT or balancing hormones does not establish that it treats the actual skin problem. The first task is to identify the condition and its pattern rather than infer a complete endocrine explanation from appearance alone.
Why does acne sometimes appear after treatment begins?
A treatment-related increase in androgen exposure can contribute to oiliness and acne. Testosterone product information lists acne among possible adverse reactions, while NIAMS explains how increased androgen signaling can enlarge oil glands and increase sebum. An outbreak after starting therapy is therefore biologically plausible. 1 2
Timing alone is not proof of the entire cause. Family tendency, occlusive products, friction, medications and other factors can contribute. NIAMS notes that pressure from clothing or equipment, picking and harsh scrubbing can worsen acne. More aggressive washing may therefore aggravate the problem rather than correct it. 1
Record where lesions appear, whether there are blackheads or whiteheads, whether they are itchy or painful and whether they leave marks or scars. These details help distinguish acne from other eruptions. A clinician can assess the skin while the prescribing team reviews whether testosterone exposure and monitoring remain appropriate.
Which patterns should be distinguished before treatment?
The appearance and distribution guide the next question. Similar-looking complaints can need different assessments, so avoid applying a single hormone explanation to every rash or hair change.
| Observed change | Question to investigate | Why the distinction matters |
|---|---|---|
| Comedones and inflamed pimples on face, chest or back | Is this acne, and how severe is it? 1 | Treatment targets follicular blockage and inflammation. |
| Irritation concentrated where gel is applied | Is this a local product reaction? 2 | A route or application issue differs from systemic androgen-related acne. |
| Gradual thinning in a typical scalp pattern | Is androgenetic hair loss present? 3 | DHT-pathway evidence concerns this condition, not every cause of shedding. |
| Abrupt, patchy or otherwise unusual hair change | Does another scalp or medical condition need assessment? | Do not assume a testosterone adjustment supplies the diagnosis. |
| Deep painful lesions or scarring | Is prompt dermatologic treatment needed? 4 | Waiting for hormone levels alone can leave the skin disease undertreated. |
The table is an assessment framework rather than a diagnostic tool. A photograph series taken under consistent lighting can document change for a clinician, but it does not replace examination or establish causation.

Does TRT inevitably cause male pattern baldness?
No. The reviewed evidence does not support an inevitable outcome or a reliable percentage risk for every man receiving replacement. Androgenetic alopecia is an androgen-sensitive condition, but susceptibility and the condition's existing course matter. Trials of DHT-pathway medicines demonstrate the pathway's relevance without establishing the probability that a particular TRT regimen will accelerate thinning. 3
For example, a randomized 24-week trial compared dutasteride, finasteride and placebo in men with androgenetic alopecia and measured changes in hair count and width. Participants were selected for hair loss, not for newly starting replacement testosterone. It would be inappropriate to turn that study into a quantified TRT hair-loss risk. 3
The useful clinical record includes whether thinning predated therapy, its progression and other changes occurring at the same time. The question is whether the treatment is contributing to an identified hair disorder, and how the benefit of testosterone compares with that burden. A family history can inform the discussion, but it does not determine an inevitable timeline.
Do acne or hair loss prove the testosterone level is too high?
No. A tissue response is not a substitute for a correctly timed blood test. Skin and hair follicles respond to local biology as well as circulating hormone, while a laboratory result itself must be interpreted against the product and administration timing. 2 3 5
If testosterone is being prescribed, review the actual formulation, recent changes, administration consistency and the timing of the sample. A high peak and an appropriate trough are different pieces of information; a number from the wrong point in a regimen can be misleading. The gel versus injection article explains those timing differences.
A level within the intended range does not make a distressing adverse effect irrelevant. Conversely, the presence of acne does not establish that the prescribed amount should simply be reduced. Assessment needs both the clinical problem and the exposure data. The goal is a treatment plan that remains useful and tolerable.

What treatments have evidence for acne and pattern hair loss?
For acne, the American Academy of Dermatology guideline supports treatments that address different mechanisms, including benzoyl peroxide, topical retinoids and selected antibiotics. It recommends limiting systemic antibiotic use and combining antibiotics with appropriate topical treatment. More severe or scarring disease can need specialist treatment, including isotretinoin when indicated. 4
For pattern hair loss, randomized trials support treatment directed at the DHT pathway, but those medicines bring their own considerations. Evidence that a medicine treats androgenetic alopecia does not mean every man on TRT should take it preemptively. The diagnosis, preferences, adverse effects and other health questions need a separate decision. 3
Adding an estrogen-lowering medicine is not a general solution for acne or scalp thinning. The 2024 acne guideline does not treat a testosterone prescription as an instruction to add another hormone drug. An evidence-based plan addresses the diagnosed skin condition and reviews the replacement therapy rather than layering unverified assumptions onto it.
How should skin and hair changes be included in a TRT review?
Treat them as outcomes that matter to the patient. At follow-up, describe the onset, progression, severity and effect on daily life. Bring a full medication and supplement list and mention any recent product switch. That makes it easier to decide whether the problem involves androgen exposure, a local reaction or a condition requiring its own treatment.
The side-effect review should also retain the less visible issues, including hematocrit and blood pressure. A clear complexion cannot prove those results are normal, just as acne cannot diagnose their abnormality. Different tissues require different assessments. 2 5
Skin and scalp outcomes are valuable signals of tolerability but poor stand-alone hormone meters. Keeping both ideas in view avoids dismissing a visible problem and avoids using it to make unsupported dosing decisions. Early assessment is particularly useful when lesions are painful, scarring or changing rapidly. 1 4
Common questions
Will switching from injections to gel stop acne?
Can a DHT blood test predict whether I will lose scalp hair?
The studies discussed here do not validate a blood-test threshold that predicts individual hair loss during TRT. Scalp pattern, history and examination are more informative than treating one hormone number as a forecast.3
References
- 1.NIAMS. Acne: Types, Causes, and Risk Factors.
- 2.ASCEND Therapeutics. AndroGel 1.62% prescribing information. DailyMed, revised October 2025.
- 3.Gubelin Harcha W, et al. A randomized, active- and placebo-controlled study of dutasteride versus placebo and finasteride in male androgenetic alopecia. JAAD. 2014.
- 4.American Academy of Dermatology. Acne clinical guideline. 2024.
- 5.Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM. 2018.
This article is for general education, not medical advice, diagnosis or a treatment recommendation. A licensed clinician can interpret the evidence in the context of your symptoms, tests, medicines and fertility plans.